PRM-151

Status
Phase 3
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

PRM-151 is an anti-fibrotic immunomodulator being developed for treatment of fibrotic diseases.

Study Purpose

This Phase III Study will Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of PRM-151 Compared with Placebo in Participants with Idiopathic Pulmonary Fibrosis (IPF).

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >